AB Science S.A.

Paris Stock Exchange AB.PA

AB Science S.A. Capital Expenditure for the year ending December 31, 2023: USD -380.79 K

AB Science S.A. Capital Expenditure is USD -380.79 K for the year ending December 31, 2023, a 44.74% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

AB Science S.A. Capital Expenditure for the year ending December 31, 2022 was USD -689.04 K, a -7.32% change year over year.
AB Science S.A. Capital Expenditure for the year ending December 31, 2021 was USD -642.03 K, a -42.05% change year over year.
AB Science S.A. Capital Expenditure for the year ending December 31, 2020 was USD -451.98 K, a -3.27% change year over year.
AB Science S.A. Capital Expenditure for the year ending December 31, 2019 was USD -437.67 K, a 20.99% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Paris Stock Exchange: AB.PA

AB Science S.A.

CEO	Mr. Alain Moussy MBA
IPO Date	April 26, 2010
Location	France
Headquarters	3, Avenue George V
Employees	40
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Vaccines

Description

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Key trends

Past 5 years